Boeing (BA.US) might be seen as one of the winners of the so-called rotation trade, which occurred in November. Stock gained over 60% as investors bet that the airline industry would recover sooner than previously expected due to mass vaccination programmes. In fact, the United Kingdom started such programme today and the first person received Covid-19 vaccine.
However, Boeing’s data, which was released today, suggests that the company lost another 63 orders for its newly un-grounded 737 MAX jet in November. The total backlog declined again as Boeing lost a net total of 28 orders. What is more, the firm delivered only 7 aircraft to customers (merely one of them was a passenger plane) in November, down from 24 in the same month a year ago.
Start investing today or test a free demo
Open real account TRY DEMO Download mobile app Download mobile appThe conclusion is quite clear: in spite of coronavirus vaccine hopes, the aviation industry still struggles heavily. According to Reuters, Boeing delivered 118 jets this year while its European rival - Airbus (AIR.DE) - as much as 477 (out of which 64 in November). Therefore, the gap between those two companies is not likely to narrow in the near-future (we have covered this issue in our “Stock of the week: Boeing” commentary from November 26).
Boeing shares are falling nearly 1% today. The price have stabilised in the past few days. Should market bulls regain control, their first target might be the $249 area (the 61.8% Fibo retracement of the coronavirus sell-off). Source: xStation5
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
